Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies
Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies
复制标题
DOI：
10.1158/1078-0432.ccr-1405-2
复制
发表时间：
2004-01-01
影响因子：
11.5
通讯作者：
Yeatman, TJ
中科院分区：
文献类型：
--
作者：
Coppola, D;Szabo, M;Yeatman, TJ
目的：骨桥蛋白（OPN）是一种整合素结合蛋白，在各种恶性肿瘤实验模型中过度表达，似乎参与肿瘤发生和转移。尽管各种研究评估了几种肿瘤类型中的 OPN 蛋白水平，但尚未对相同实验条件下的人类肿瘤中 OPN 表达进行广泛调查。 实验设计：我们使用分期导向的人类癌症组织阵列，使用免疫组织化学方法检测来自不同身体部位的 350 个人类肿瘤和 113 个正常组织中的 OPN。肿瘤包括乳腺癌（26）、卵巢（22）、子宫内膜（14）、食道（10）、胃（11）、胰腺（16）、胆管（1）、肝脏（9）、结肠（20）、肾（53）、膀胱（33）、前列腺（28）、头颈（60）、唾液腺（14）、肺（17）、皮肤恶性肿瘤 (6) 和脑 (10)。结果：在 100% 的胃癌、85% 的结直肠癌、82% 的肾盂移行细胞癌、81% 的胰腺癌、72% 的肾细胞癌、71% 的肺癌和子宫内膜癌中观察到高细胞质 OPN 染色 癌，70% 的食管癌，58% 的头颈部鳞状细胞癌，59% 的卵巢癌。尽管在大量膀胱癌、前列腺癌和脑肿瘤中发现了 OPN 表达，但大多数 6 种皮肤癌、14 种唾液腺癌中的 11 种、2 种甲状腺癌和 26 种乳腺癌中的 23 种显示 OPN 低阳性或阴性。当考虑所有位点时，OPN 表达与肿瘤分期显着相关（Spearman 相关系数，P = 0.0002）。 OPN 评分和分期也与特定癌症部位显着相关，包括膀胱 (P = 0.01)、结肠 (P = 0.004)、肾脏 (P = 0.0001)、喉 (P = 0.035)、口腔 (P = 0.046) 和唾液腺 (P = 0.011)。 结论：这项研究报告了 OPN 在不同身体部位的人类肿瘤中的广泛分布，表明这个 肿瘤形成中的蛋白质。多种肿瘤类型的病理分期和 OPN 之间的强相关性表明 OPN 在肿瘤进展中发挥作用。
Purpose: Osteopontin (OPN) is an integrin-binding protein overexpressed in various experimental models of malignancy and appears to be involved in tumorigenesis and metastasis. Although various studies have assessed OPN protein levels in several tumor types, a broad survey of OPN expression in human neoplasia under the same experimental conditions has not been carried out.Experimental Design: We used immunohistochemistry to detect OPN in a selection of 350 human tumors and 113 normal tissues, from a variety of body sites, using stage-oriented human cancer tissue arrays. Tumors included malignancies from breast (26), ovary (22), endometrium (14), esophagus (10), stomach (11), pancreas (16), bile duct (1), liver (9), colon (20), kidney (53), bladder (33), prostate (28), head and neck (60), salivary glands (14), lung (17), skin (6), and brain (10).Results: High cytoplasmic OPN staining was observed in 100% of gastric carcinomas, 85% of colorectal carcinomas, 82% of transitional cell carcinomas of the renal pelvis, 81% of pancreatic carcinomas, 72% of renal cell carcinomas, 71% of lung and endometrial carcinomas, 70% of esophageal carcinomas, 58% of squamous cell carcinomas of the head and neck, and 59% of ovarian carcinomas. Although OPN expression was identified in a good number of bladder, prostate, and brain tumors, the majority of 6 skin cancers, 11 of 14 salivary gland cancers, 2 thyroid carcinomas, and 23 of 26 breast cancers revealed low OPN positivity or were negative. When considering all sites, OPN expression significantly correlated with tumor stage (Spearman's correlation coefficient, P = 0.0002). OPN score and stage were also significantly correlated for specific cancer sites including bladder (P = 0.01), colon (P = 0.004), kidney (P = 0.0001), larynx (P = 0.035), mouth (P = 0.046), and salivary gland (P = 0.011).Conclusions: This study reports the broad distribution of OPN in human tumors from different body sites, suggesting involvement of this protein in tumor formation. The strong correlation between pathological stage and OPN across multiple tumor types suggests a role for OPN in tumor progression.